# US 10,864,226 B2 · Use of microRNA-188-5p for treating Alzheimer's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,226 B2
- Document ID: US10864226B2
- Status: Granted
- Kind: B2
- Application number: 16/465,865
- Filed: 2017-04-06
- Published: 2019-10-03
- Granted: 2020-12-15
- Earliest claimed: 2017-04-06
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R&Db Foundation
- Inventors: Hye Sun Kim; Kihwan Lee; Hyunju Kim
- Web page: https://patentgrep.com/patent/US10864226B2

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/321: 2'-O-R Modification
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a use of microRNA(miR)-188-5p which can be used for treatment of Alzheimer's disease, and the pharmaceutical composition comprising miR-188-5p as an active ingredient of the present invention can inhibit the expression of NRP2 protein when it is added to a subject having Alzheimer's disease, thereby restoring the reduced density of dendritic spines and enhancing synaptic transmission, and thus it can prevent or treat Alzheimer's disease effectively.

## Claims

### Claim 1

A method for preventing or treating Alzheimer's disease comprising:
administering an effective amount of a composition comprising miR-188-5p to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the miR-188-5p consists of the sequence represented by SEQ ID NO: 1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the miR-188-5p inhibits expression of Nrp2 mRNA into a protein.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the composition comprises a pre-miRNA (precursor) of miR-188-5p.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the sequence of the pre-miRNA of miR-188-5p consists of the sequence represented by SEQ ID NO: 4.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition comprises an expression vector containing a polynucleotide encoding miR-188-5p.

### Claim 7

A method for restoring cognitive function related to Alzheimer's disease comprising:
administering an effective amount of miR-188-5p to a subject in need thereof.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the miR-188-5p consists of the sequence represented by SEQ ID NO: 1.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the miR-188-5p inhibits expression of Nrp2 mRNA into a protein.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the composition comprises a pre-miRNA (precursor) of miR-188-5p.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the sequence of the pre-miRNA of miR-188-5p consists of the sequence represented by SEQ ID NO: 4.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the composition comprises an expression vector containing a polynucleotide encoding miR-188-5p.